159 related articles for article (PubMed ID: 14706684)
1. Gene expression patterns that characterize advanced stage serous ovarian cancers.
Lancaster JM; Dressman HK; Whitaker RS; Havrilesky L; Gray J; Marks JR; Nevins JR; Berchuck A
J Soc Gynecol Investig; 2004 Jan; 11(1):51-9. PubMed ID: 14706684
[TBL] [Abstract][Full Text] [Related]
2. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
Lancaster JM; Sayer R; Blanchette C; Calingaert B; Whitaker R; Schildkraut J; Marks J; Berchuck A
Clin Cancer Res; 2003 Feb; 9(2):762-6. PubMed ID: 12576447
[TBL] [Abstract][Full Text] [Related]
3. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
4. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
Engler DA; Gupta S; Growdon WB; Drapkin RI; Nitta M; Sergent PA; Allred SF; Gross J; Deavers MT; Kuo WL; Karlan BY; Rueda BR; Orsulic S; Gershenson DM; Birrer MJ; Gray JW; Mohapatra G
PLoS One; 2012; 7(2):e30996. PubMed ID: 22355333
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
[TBL] [Abstract][Full Text] [Related]
6. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
Sayer RA; Lancaster JM; Pittman J; Gray J; Whitaker R; Marks JR; Berchuck A
Gynecol Oncol; 2005 Feb; 96(2):355-61. PubMed ID: 15661221
[TBL] [Abstract][Full Text] [Related]
7. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
8. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
Lancaster JM; Sayer RA; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg DW; Marks JR; Berchuck A
Int J Gynecol Cancer; 2006; 16(4):1529-35. PubMed ID: 16884361
[TBL] [Abstract][Full Text] [Related]
9. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
12. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL
J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
14. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
Berchuck A; Iversen ES; Lancaster JM; Dressman HK; West M; Nevins JR; Marks JR
Am J Obstet Gynecol; 2004 Apr; 190(4):910-25. PubMed ID: 15118612
[TBL] [Abstract][Full Text] [Related]
15. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
Berchuck A; Iversen ES; Lancaster JM; Pittman J; Luo J; Lee P; Murphy S; Dressman HK; Febbo PG; West M; Nevins JR; Marks JR
Clin Cancer Res; 2005 May; 11(10):3686-96. PubMed ID: 15897565
[TBL] [Abstract][Full Text] [Related]
16. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
17. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.
Cheon DJ; Tong Y; Sim MS; Dering J; Berel D; Cui X; Lester J; Beach JA; Tighiouart M; Walts AE; Karlan BY; Orsulic S
Clin Cancer Res; 2014 Feb; 20(3):711-23. PubMed ID: 24218511
[TBL] [Abstract][Full Text] [Related]
18. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
Birrer MJ; Johnson ME; Hao K; Wong KK; Park DC; Bell A; Welch WR; Berkowitz RS; Mok SC
J Clin Oncol; 2007 Jun; 25(16):2281-7. PubMed ID: 17538174
[TBL] [Abstract][Full Text] [Related]
19. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
[TBL] [Abstract][Full Text] [Related]
20. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.
Vathipadiekal V; Saxena D; Mok SC; Hauschka PV; Ozbun L; Birrer MJ
PLoS One; 2012; 7(1):e29079. PubMed ID: 22272227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]